Job Van Riet

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications

Tumor Whole-Genome Sequencing for Prediction of Venous Thromboembolism in Patients With Metastasized Solid Cancer.

Tumor Whole-Genome Sequencing for Prediction of Venous Thromboembolism in Patients With Metastasized Solid Cancer.

Journal: Circulation. Genomic and precision medicine
Published: April 10, 2026

The Impact of Spliceosome Inhibition in SF3B1-Mutated Uveal Melanoma.

The Impact of Spliceosome Inhibition in SF3B1-Mutated Uveal Melanoma.

Journal: Investigative ophthalmology & visual science
Published: October 07, 2024

Cell-free DNA aneuploidy score as a dynamic early response marker in prostate cancer.

Cell-free DNA aneuploidy score as a dynamic early response marker in prostate cancer.

Journal: Molecular oncology
Published: July 25, 2024

Four Core Genotypes mice harbour a 3.2MB X-Y translocation that perturbs Tlr7 dosage.

Four Core Genotypes mice harbour a 3.2MB X-Y translocation that perturbs Tlr7 dosage.

Journal: Nature communications
Published: December 21, 2023

The Germline and Somatic Origins of Prostate Cancer Heterogeneity.

The Germline and Somatic Origins of Prostate Cancer Heterogeneity.

Journal: Cancer discovery
Published: August 03, 2023

Katdetectr: an R/bioconductor package utilizing unsupervised changepoint analysis for robust kataegis detection.

Katdetectr: an R/bioconductor package utilizing unsupervised changepoint analysis for robust kataegis detection.

Journal: GigaScience
Published: February 24, 2023

A Compendium of AR Splice Variants in Metastatic Castration-Resistant Prostate Cancer.

A Compendium of AR Splice Variants in Metastatic Castration-Resistant Prostate Cancer.

Journal: International journal of molecular sciences
Published: January 31, 2023

mFast-SeqS-based aneuploidy score in circulating cell-free DNA is a prognostic biomarker in prostate cancer.

mFast-SeqS-based aneuploidy score in circulating cell-free DNA is a prognostic biomarker in prostate cancer.

Journal: Molecular oncology
Published: January 19, 2023

Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors.

Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: October 14, 2022

Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning.

Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning.

Journal: Nature communications
Published: September 09, 2022

Tobacco Smoking-Related Mutational Signatures in Classifying Smoking-Associated and Nonsmoking-Associated NSCLC.

Tobacco Smoking-Related Mutational Signatures in Classifying Smoking-Associated and Nonsmoking-Associated NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: July 19, 2022

CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients.

CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients.

Journal: European journal of cancer (Oxford, England : 1990)
Published: July 08, 2022
Showing 1-12 of 38

Last Updated: 09/26/2026